Stay updated with breaking news from Gary patou. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target raised by Bank of America from $52.00 to $56.00 in a research report sent to investors on Tuesday, Benzinga reports. Bank of America currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on XENE. StockNews.com […] ....
Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $54.00 to $59.00 in a report published on Tuesday morning, BayStreet.CA reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on XENE. Stifel Nicolaus […] ....
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $54.00 to $59.00 in a note issued to investors on Tuesday, BayStreet.CA reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective points to a […] ....
Phase 1 clinical trial advances with first subject dosed in the E.U. and IND accepted in the U.S. Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare ....
Advisors Asset Management Inc. lowered its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 18.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,121 shares of the biopharmaceutical company’s stock after selling 927 shares during the quarter. Advisors Asset […] ....